JP2008500320A5 - - Google Patents

Download PDF

Info

Publication number
JP2008500320A5
JP2008500320A5 JP2007514117A JP2007514117A JP2008500320A5 JP 2008500320 A5 JP2008500320 A5 JP 2008500320A5 JP 2007514117 A JP2007514117 A JP 2007514117A JP 2007514117 A JP2007514117 A JP 2007514117A JP 2008500320 A5 JP2008500320 A5 JP 2008500320A5
Authority
JP
Japan
Prior art keywords
pyrimidin
thiazol
methyl
phenyl
amine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007514117A
Other languages
English (en)
Japanese (ja)
Other versions
JP5026259B2 (ja
JP2008500320A (ja
Filing date
Publication date
Priority claimed from GBGB0411791.7A external-priority patent/GB0411791D0/en
Application filed filed Critical
Publication of JP2008500320A publication Critical patent/JP2008500320A/ja
Publication of JP2008500320A5 publication Critical patent/JP2008500320A5/ja
Application granted granted Critical
Publication of JP5026259B2 publication Critical patent/JP5026259B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2007514117A 2004-05-26 2005-05-26 増殖性障害の治療に有用な2−置換−4−ヘテロアリール−ピリミジン Expired - Fee Related JP5026259B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0411791.7A GB0411791D0 (en) 2004-05-26 2004-05-26 Compounds
GB0411791.7 2004-05-26
PCT/GB2005/002134 WO2005116025A2 (en) 2004-05-26 2005-05-26 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders

Publications (3)

Publication Number Publication Date
JP2008500320A JP2008500320A (ja) 2008-01-10
JP2008500320A5 true JP2008500320A5 (https=) 2008-06-19
JP5026259B2 JP5026259B2 (ja) 2012-09-12

Family

ID=32671118

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007514117A Expired - Fee Related JP5026259B2 (ja) 2004-05-26 2005-05-26 増殖性障害の治療に有用な2−置換−4−ヘテロアリール−ピリミジン

Country Status (11)

Country Link
US (1) US20090137572A1 (https=)
EP (1) EP1756098A2 (https=)
JP (1) JP5026259B2 (https=)
CN (1) CN1989138A (https=)
AU (1) AU2005247682A1 (https=)
BR (1) BRPI0511616A (https=)
CA (1) CA2566051A1 (https=)
GB (1) GB0411791D0 (https=)
IL (1) IL179508A0 (https=)
MX (1) MXPA06013632A (https=)
WO (1) WO2005116025A2 (https=)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0205688D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
GB0205693D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
US7442697B2 (en) 2002-03-09 2008-10-28 Astrazeneca Ab 4-imidazolyl substituted pyrimidine derivatives with CDK inhibitory activity
GB0205690D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
GB0311274D0 (en) 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
GB0311276D0 (en) 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
CA2583812A1 (en) * 2004-10-28 2006-05-11 Irm Llc Compounds and compositions as hedgehog pathway modulators
CN101203500B (zh) * 2005-01-25 2013-08-21 格利尼公司 取代的芳胺化合物和它们作为5-ht6调节剂的用途
US7968538B2 (en) * 2005-01-25 2011-06-28 Galenea Corp. Substituted arylamine compounds and methods of treatment
WO2007084391A2 (en) 2006-01-18 2007-07-26 Amgen Inc. Thiazole compounds as protein kinase b ( pkb) inhibitors
GB0609530D0 (en) * 2006-05-12 2006-06-21 Cyclacel Ltd Combination
WO2007132221A1 (en) * 2006-05-12 2007-11-22 Cyclacel Limited Combined anticancer pyrimidine-thiazole aurora kinase inhibitors
WO2007132220A1 (en) * 2006-05-12 2007-11-22 Cyclacel Limited Combination of a 2-substituted-4-heter0aryl-pyrimidine amine with a cytotoxic drug and use thereof in the treatment of a proliferative disorder
US7919504B2 (en) 2007-07-17 2011-04-05 Amgen Inc. Thiadiazole modulators of PKB
EP2173728A2 (en) 2007-07-17 2010-04-14 Amgen Inc. Heterocyclic modulators of pkb
WO2009032667A1 (en) * 2007-08-29 2009-03-12 Smithkline Beecham Corporation Thiazole and oxazole kinase inhibitors
ATE510827T1 (de) * 2007-10-12 2011-06-15 Ingenium Pharmaceuticals Gmbh Inhibitoren von proteinkinasen
WO2009076140A1 (en) * 2007-12-13 2009-06-18 Smithkline Beecham Corporation Thiazole and oxazole kinase inhibitors
HUE030912T2 (en) 2008-02-15 2017-06-28 Rigel Pharmaceuticals Inc Pyrimidine-2-amine compounds and their use as inhibitors of yak kinases
GB0805477D0 (en) * 2008-03-26 2008-04-30 Univ Nottingham Pyrimidines triazines and their use as pharmaceutical agents
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
US8765747B2 (en) 2009-06-12 2014-07-01 Dana-Farber Cancer Institute, Inc. Fused 2-aminothiazole compounds
US20120301463A1 (en) 2009-09-30 2012-11-29 President And Fellows Of Harvard College Methods for Modulation of Autophagy Through the Modulation of Autophagy-Enhancing Gene Products
EP2498608A4 (en) * 2009-11-10 2013-04-24 Glaxosmithkline Llc BENZOLSULFONAMIDE THIAZOL AND OXAZOLE COMPOUNDS
WO2011090738A2 (en) 2009-12-29 2011-07-28 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
CN103403002B (zh) * 2011-02-24 2016-06-22 内尔维阿诺医学科学有限公司 作为激酶抑制剂的噻唑基苯基-苯磺酰氨基衍生物
US9498471B2 (en) 2011-10-20 2016-11-22 The Regents Of The University Of California Use of CDK9 inhibitors to reduce cartilage degradation
US9382239B2 (en) 2011-11-17 2016-07-05 Dana-Farber Cancer Institute, Inc. Inhibitors of c-Jun-N-terminal kinase (JNK)
EP2909194A1 (en) 2012-10-18 2015-08-26 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
USRE48175E1 (en) 2012-10-19 2020-08-25 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
WO2014063054A1 (en) 2012-10-19 2014-04-24 Dana-Farber Cancer Institute, Inc. Bone marrow on x chromosome kinase (bmx) inhibitors and uses thereof
WO2015058126A1 (en) 2013-10-18 2015-04-23 Syros Pharmaceuticals, Inc. Heteroaromatic compounds useful for the treatment of prolferative diseases
EP3057956B1 (en) 2013-10-18 2021-05-05 Dana-Farber Cancer Institute, Inc. Polycyclic inhibitors of cyclin-dependent kinase 7 (cdk7)
CN110229142A (zh) * 2014-04-04 2019-09-13 希洛斯医药品股份有限公司 细胞周期蛋白依赖性激酶7(cdk7)的抑制剂
US9862688B2 (en) 2014-04-23 2018-01-09 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged janus kinase inhibitors and uses thereof
WO2015164614A1 (en) 2014-04-23 2015-10-29 Dana-Farber Cancer Institute, Inc. Janus kinase inhibitors and uses thereof
CA3000633C (en) 2014-10-14 2023-10-03 The Regents Of The University Of California Use of cdk9 and brd4 inhibitors to inhibit inflammation
JP6854762B2 (ja) 2014-12-23 2021-04-07 ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド サイクリン依存性キナーゼ7(cdk7)の阻害剤
USRE50776E1 (en) 2015-03-27 2026-02-03 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
WO2016201370A1 (en) 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
USRE49850E1 (en) * 2015-08-04 2024-02-27 Aucentra Therapeutics Pty Ltd N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amine derivatives as therapeutic compounds
AU2016319125B2 (en) 2015-09-09 2021-04-08 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
EP3740484B1 (en) * 2018-01-15 2024-09-11 Aucentra Therapeutics Pty Ltd 5-(pyrimidin-4-yl)thiazol-2-yl urea derivatives as therapeutic agents
EP3810132A4 (en) 2018-06-25 2022-06-22 Dana-Farber Cancer Institute, Inc. TAIRE FAMILY KINASE INHIBITORS AND RELATED USES
CN111039941B (zh) * 2018-10-12 2023-03-21 上海医药集团股份有限公司 一种含氮杂环化合物、其制备方法及应用
US12281126B2 (en) 2018-12-28 2025-04-22 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 and uses thereof
WO2024259116A1 (en) * 2023-06-14 2024-12-19 Prothena Biosciences Limited 5-(cinnolin-6-yl)thiazole compounds for treating neurological disorders
CN116903592B (zh) * 2023-07-13 2025-08-01 特科罗生物科技(成都)有限公司 一种嘧啶胺类nuak抑制剂及其制备方法和用途
WO2026024674A1 (en) 2024-07-22 2026-01-29 Genesis Therapeutics, Inc. Methods of treating skp2-associated cancers

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5516775A (en) * 1992-08-31 1996-05-14 Ciba-Geigy Corporation Further use of pyrimidine derivatives
BR9407799A (pt) * 1993-10-12 1997-05-06 Du Pont Merck Pharma Composição de matéria método de tratamento e composição farmaceutica
GB9519275D0 (en) * 1995-09-21 1995-11-22 Univ Dundee Substances and their therapeutic use
GB9523675D0 (en) * 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
DE69736351D1 (de) * 1996-05-08 2006-08-31 Cyclacel Ltd Methoden und mittel zur hemmung der cdk4-aktivität
AU753015B2 (en) * 1998-03-04 2002-10-03 Cyclacel Limited Cyclin dependent kinase inhibitor
US6703395B2 (en) * 1998-03-04 2004-03-09 Institute Of Experimental Botany Of The Academy Of Sciences Of The Czech Republic Cyclin dependent kinase inhibitor
WO1999065897A1 (en) * 1998-06-19 1999-12-23 Chiron Corporation Inhibitors of glycogen synthase kinase 3
US7045519B2 (en) * 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
CN100355751C (zh) * 2000-03-29 2007-12-19 西克拉塞尔有限公司 2-取代的4-杂芳基-嘧啶、其组合物及其用途
GB0107901D0 (en) * 2001-03-29 2001-05-23 Cyclacel Ltd Anti-cancer compounds
ES2274035T3 (es) * 2001-06-01 2007-05-16 Vertex Pharmaceuticals Incorporated Compuestos de tiazol utiles como inhibidores de proteina quinasas.
US20040181066A1 (en) * 2001-08-01 2004-09-16 Fraley Mark E. Tyrosine kinase inhibitors
CN100500663C (zh) * 2001-09-28 2009-06-17 西克拉塞尔有限公司 作为抗增殖化合物的n-(4-(4-甲基噻唑-5-基)嘧啶-2-基)-n-苯胺
GB0226583D0 (en) * 2002-11-14 2002-12-18 Cyclacel Ltd Compounds
GB0226582D0 (en) * 2002-11-14 2002-12-18 Cyclacel Ltd Anti-viral compounds
GB0229581D0 (en) * 2002-12-19 2003-01-22 Cyclacel Ltd Use
CA2523125A1 (en) * 2003-03-25 2004-10-14 Vertex Pharmaceuticals Incorporated Thiazoles useful as inhibitors of protein kinases
JP2007500178A (ja) * 2003-07-30 2007-01-11 サイクラセル・リミテッド プロテインキナーゼ阻害剤としてのピリジニルアミノ−ピリミジン誘導体
EP1648875A1 (en) * 2003-07-30 2006-04-26 Cyclacel Limited 2-aminophenyl-4-phenylpyrimidines as kinase inhibitors
JP5164380B2 (ja) * 2003-10-21 2013-03-21 サイクラセル リミテッド ピリミジン−4−イル−3,4−チオン化合物及び治療におけるその使用
JPWO2005113550A1 (ja) * 2004-05-20 2008-03-27 三菱ウェルファーマ株式会社 アミノピリミジン誘導体及びその医薬としての用途

Similar Documents

Publication Publication Date Title
JP2008500320A5 (https=)
JP2007520540A5 (https=)
JP2007509117A5 (https=)
US20090137572A1 (en) 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders
RU2008117170A (ru) Пиримидинамидные соединения как ингибиторы pgds
RU2454415C9 (ru) Производное индола
JP2008524248A5 (https=)
RU2426731C2 (ru) Производные арил-изоксазоло-4-ил-оксадиазола
JP2013517273A5 (https=)
JP2007523142A5 (https=)
CA2590939A1 (en) Aminopyrimidine compounds and methods of use
US20040110810A1 (en) 2-(3-Aminoaryl)amino-4-aryl-thiazoles for the treatment of diseases
JP2011526616A5 (https=)
JP2018048190A (ja) ヒトプロテインチロシンホスファターゼ阻害剤および使用法
JP2010215644A5 (https=)
JP2015533157A5 (https=)
JP2014511869A5 (https=)
RU2010115574A (ru) Замещенные амиды, фармацевтическая композиция на их основе, способ лечения заболевания, чувствительного к btk, способ повышения чувствительности раковых клеток к химиотерапии, способ уменьшения ошибок при приеме лекарства и улучшения соблюдения схемы лечения, способ ингибирования гидролиза атф, способ определения присутствия btk в образце и способ ингибирования активности в-клеток
JP2002332266A (ja) PPAR−γモジュレータ
JP2009542659A5 (https=)
JP2008519850A5 (https=)
JP2011523646A5 (https=)
JP2007508346A5 (https=)
JP2003525872A5 (https=)
JP2018507234A5 (https=)